MBTPS1 and chronic kidney disease: This chapter summarizes the effects of established treatment strategies for CKD, including glucocorticoids, sodium-glucose co-transporter 2 inhibitors (SGLT2i), angiotensin-converting enzyme inhibitors (ACEi), and angiotensin II receptor blockers (ARB) on the S1P pathway since an increasing amount of data suggest that the efficacy of these treatments may be partially mediated through the modulation of S1P levels or S1P signaling.